Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.08 USD | -1.28% | -8.88% | -38.03% |
May. 15 | PDS Biotechnology Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 10 | NetScientific says PDS Biotech's Versamune meets endpoints | AN |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 367K | Capitalization | 113M |
---|---|---|---|---|---|
Net income 2024 * | -49M | Net income 2025 * | -63M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 308 x |
P/E ratio 2024 * |
-2.31
x | P/E ratio 2025 * |
-2.04
x | Employees | 25 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.22% |
Latest transcript on PDS Biotechnology Corporation
1 day | -1.28% | ||
1 week | -8.88% | ||
Current month | -8.06% | ||
1 month | -5.81% | ||
3 months | -49.51% | ||
6 months | -47.80% | ||
Current year | -38.03% |
Managers | Title | Age | Since |
---|---|---|---|
Frank Bedu-Addo
FOU | Founder | 59 | 19-03-14 |
Director of Finance/CFO | 55 | Dec. 03 | |
David Schaaf
CTO | Chief Tech/Sci/R&D Officer | - | 22-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Stephen Glover
CHM | Chairman | 60 | 19-04-01 |
Otis Brawley
BRD | Director/Board Member | 64 | 20-11-02 |
Richard Sykes
BRD | Director/Board Member | 79 | 19-02-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +4.20% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 3.08 | -1.28% | 502,307 |
24-05-23 | 3.12 | -7.69% | 597,556 |
24-05-22 | 3.38 | -5.06% | 350,887 |
24-05-21 | 3.56 | +5.33% | 734,254 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.03% | 113M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-0.29% | 22.1B | |
-9.28% | 18.34B | |
-41.70% | 16.59B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- PDSB Stock